LINC00316

Across TCGA pan-cancer cohorts, LINC00316 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of LINC00316’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where LINC00316 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00316 is over-expressed in tumor, although a few such as LUSC and PAAD show the opposite, repressed pattern.

CHOL, LUSC, and LIHC are the cancer types where LINC00316 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00316 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	Female	All	+1.020	<.001	5	view →
LUSC	All	II,III,IV	−0.235	.001	5	view →
LIHC	All	All	+0.113	<.001	5	view →
PAAD	Female	All	−0.459	.006	4	view →
KIRP	All	III,IV	+0.238	.018	4	view →
LUAD	All	III,IV	−0.302	.013	3	view →
THCA	Male	All	−0.372	.006	2	view →
KICH	All	All	−0.147	.007	2	view →
HNSC	All	All	+0.057	.038	2	view →
BLCA	All	III,IV	−0.232	.046	1	view →
COAD	Male	III,IV	−0.128	.032	1	view →
STAD	Male	II,III,IV	−0.083	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

LINC00316–CHOL

Open the CHOL breakdown →